Retrospective study on clinical efficacy of Evolocumab in high-risk ASCVD patients

Fatima Mohamed Alzaabi; Semira Abdi Beshir; Emad Abdel Fattah; Syed Wasif Gillani

Ayuda

Retrospective study on clinical efficacy of Evolocumab in high-risk ASCVD patients

Fatima Mohamed Alzaabi ^[1] ; Semira Abdi Beshir ^[2] ; Emad Abdel Fattah ^[3] ; Syed Wasif Gillani ^[4]
1. [1] Military Hospital
  
  Military Hospital
  
  Pakistán
2. [2] Dubai Pharmacy College
  
  Dubai Pharmacy College
  
  Emiratos Árabes Unidos
3. [3] Zayed Military Hospital
  
  Zayed Military Hospital
  
  Emiratos Árabes Unidos
4. [4] Gulf Medical University
  
  Gulf Medical University
  
  Emiratos Árabes Unidos
Mostrar afiliaciones +
Localización: Pharmacy Practice (Granada), ISSN-e 1886-3655, Vol. 21, Nº. 2, 2023
Idioma: inglés
Enlaces
- Texto completo (pdf)
Resumen
- Objective: This study evaluated the effectiveness of Evolocumab by measuring achievement target LDL-C among high-risk ASCVD patients in the UAE. Method: A retrospective observational study included 27 patients with high-risk ASCVD receiving Evolocumab 140 mg/mL SC injection every 2 weeks. The effectiveness of Evolocumab is measured by the mean reduction in LDL-C levels from baseline and achieving target LDL levels according to ECS/EAS guideline during average follow up period. Results: The average (SD) age of the patients is 52 (10) years. Majority of the patients were male (n=22), smokers (40.9%), overweight or obese (78%), had a history of hypertension (59.3%), MI (55.5%) and diabetes (40.7%). The patients were on Evolucomab therapy due to persistently elevated LDL-C (n=25) or statin intolerance (n=2). During the average follow up period of 42 weeks,14 patients (51%) achieved target LDL-C level. During this period, LDL-C and TC levels reduced from 3.51(1.3) mmol/L to 1.9 (1.2) mmol/L and from 4.97 (1.4) mmol/L to 1.62 (1.09) mmol/L, respectively post Evolocumab therapy. Conclusion: The reduction was statistically significant. However, the reduction of TG levels and the increase in HDL level was not significant. Evolocumab reduces LDL-C and TC levels significantly in high-risk ASCVD patients in a tertiary hospital in the UAE population.